Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?

Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L45-L47. doi: 10.1152/ajplung.00124.2020. Epub 2020 Jun 10.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Humans
  • Inflammation / drug therapy
  • Pandemics
  • Peptidyl-Dipeptidase A / drug effects*
  • Pneumonia, Viral / drug therapy*
  • Proto-Oncogene Proteins c-akt / drug effects*
  • SARS-CoV-2

Substances

  • Proto-Oncogene Proteins c-akt
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2